Scaling Proteomics: Balancing Performance and Measuring Enough Proteins
Explore the advancements in proteomics platforms, with a focus on precision, sensitivity and specificity
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains?
To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
Additionally, since most proteins not yet measurable are low-abundance non-secreted proteins, the webinar will address whether credible physiological signals exist in that fraction and if expanding proteomic measurements to encompass the entire proteome is worthwhile.
Stephen Williams, MD, PhD
Chief Medical Officer
Standard BioTools
Stephen Williams, MD, PhD, is the Chief Medical Officer at Standard BioTools and oversees clinical application of the SomaScan® Platform.
Before joining Standard BioTools, Dr. Williams co-founded the pharma consultancy Decisionability, LLC and authored the book Decisionability: The skill to make your decisions productive, practical and painless. Previously, he worked at Pfizer, Inc., initially in experimental medicine and later as the Vice President and Worldwide Head of Clinical Technology. He was also on the National Advisory Council for Biomedical Imaging and Bioengineering at the U.S. National Institutes of Health. He helped launch the Alzheimer’s Disease Neuroimaging (ADNI) study and form the FDA-FNIH-PhRMA biomarker consortium. He led or co-led the PhRMA position papers on “proof of concept,” surrogate endpoints and evidentiary standards for biomarkers and diagnostics.
Dr. Williams has degrees in physiology, medicine and surgery, and received his doctorate in medicine and physiology from Charing Cross and Westminster Medical School (now a part of Imperial College, London). He also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.
Scaling proteomics: Balancing performance and measuring enough proteins
A presentation by Stephen Williams, MD, PhD
More webinars
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.
WebinarData Summit 2025
Take your research further with expert insights from the SomaScan™ Data Summit. Explore the latest platform updates, advanced data analysis tools, and innovative applications for SOMAmer™ reagents. From optimizing sample quality to customizing panels beyond 7K and 11K, this event is packed with knowledge to help you get the most from your data.